Brian McCullagh
Overview
Explore the profile of Brian McCullagh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mullen E, McCullagh B, Gaine S, Quadery S
Br J Hosp Med (Lond)
. 2025 Feb;
86(2):1-13.
PMID: 39998132
Pulmonary arterial hypertension (PAH) is a rare, progressive, debilitating and life shortening condition characterized by raised pulmonary arterial pressures. PAH includes a group of conditions sharing similar pathophysiology, clinical features...
2.
Cullivan S, Kevane B, McCullagh B, OConnor T, Condliffe R, Gaine S
Pulm Circ
. 2024 Nov;
14(4):e70007.
PMID: 39588537
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant, multisystem disorder that manifests with a spectrum of disease including cardiopulmonary complications. HHT is characterised by aberrant signalling via the transforming growth...
3.
The impact of gas transfer on responses to exercise training in patients with pulmonary hypertension
McCormack C, Kehoe B, McCullagh B, Gaine S, Moyna N, Quadery S
Pulm Circ
. 2024 Sep;
14(3):e12438.
PMID: 39323735
Exercise training is recommended for pulmonary hypertension (PH). Post hoc analysis of the PH and Home-Based (PHAHB) trial stratified patients into two groups based on median diffusing capacity of the...
4.
McCormack C, Kehoe B, Cullivan S, McCaffrey N, Gaine S, McCullagh B, et al.
ERJ Open Res
. 2024 Jan;
10(1).
PMID: 38264149
Background: Pulmonary hypertension (PH) is a heterogeneous condition, associated with a high symptom burden and a substantial loss of exercise capacity. Despite prior safety concerns regarding physical exertion, exercise training...
5.
McCormack C, Kehoe B, Cullivan S, McCaffrey N, Gaine S, McCullagh B, et al.
PLoS One
. 2023 Jan;
18(1):e0277696.
PMID: 36652433
Objective: Physical activity (PA) is an established adjunct therapy for pulmonary hypertension (PH) patients to mitigate PH symptoms and improve quality of life. However, PA engagement within this population remains...
6.
Cullivan S, Lennon D, Meghani S, Minnock C, McCullagh B, Gaine S
BMJ Open Respir Res
. 2022 Jun;
9(1).
PMID: 35768152
Introduction: Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality. The aim of this study is to define the characteristics...
7.
Cullivan S, Natarajan A, Boyle N, McCormack C, Gaine S, McCullagh B
Br J Cardiol
. 2022 Jun;
28(3):32.
PMID: 35747707
Selexipag is an oral selective prostacyclin-receptor agonist that was approved for use in patients with World Health Organisation (WHO) functional class II-III pulmonary arterial hypertension (PAH). Treatment with individualised doses...
8.
Cullivan S, McCullagh B, Gaine S
Breathe (Sheff)
. 2022 Mar;
18(1):210168.
PMID: 35284019
https://bit.ly/3rwEkhP.
9.
Kelliher S, Weiss L, Cullivan S, ORourke E, Murphy C, Toolan S, et al.
J Thromb Haemost
. 2022 Feb;
20(4):1008-1014.
PMID: 35102689
Background: Hypercoagulability and endothelial dysfunction are hallmarks of coronavirus disease 2019 (COVID-19) and appear to predict disease severity. A high incidence of thrombosis despite thromboprophylaxis is reported in patients with...
10.
McCormack C, Cullivan S, Kehoe B, McCaffrey N, Gaine S, McCullagh B, et al.
Pulm Circ
. 2021 Nov;
11(4):20458940211056509.
PMID: 34777786
Pulmonary hypertension is a progressive cardiorespiratory disease that is characterized by considerable morbidity and mortality. While physical activity can improve symptoms and quality of life, engagement in this population is...